Skip to Main Content

Author Details

Collin M Blakely
University of California san francisco
1998
48
23
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
38049664The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Nat Genet2024
36736076Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review.Lung Cancer2023
37308126Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.J Natl Compr Canc Netw2023
37068173Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.Cancer Discov2023
36879929Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter Study.JTO Clin Res Rep2023
36842467MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.J Thorac Oncol2023
36641093CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.J Thorac Oncol2023
34611887Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study.J Am Geriatr Soc2022
35353542Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.Sci Transl Med2022
36545322Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.JTO Clin Res Rep2022
35895872AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.Cancer Discov2022
34278827Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for <i>EGFR</i>-mutated resectable non-small-cell lung cancer: NeoADAURA.Future Oncol2021
34902832Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2021
34866626Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids.J Vis Exp2021
34544620Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.Clin Lung Cancer2021
32366673Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.Clin Cancer Res2020
34589984Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.JTO Clin Res Rep2020
31838007Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.Lancet Oncol2020
32997124Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.JAMA Netw Open2020
32822576Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.Cell2020
32642201Impact of concurrent genomic alterations in epidermal growth factor receptor (<i>EGFR</i>)-mutated lung cancer.J Thorac Dis2020
30538120Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.Cancer Res2019
31809604Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.Expert Rev Anticancer Ther2019
31611281A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations.Clin Cancer Res2019
30806814Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.Curr Oncol Rep2019
30553716Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.Clin Lung Cancer2019
30478424Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.Nat Med2019
28645632Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.Clin Lung Cancer2018
30104724RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.Nat Cell Biol2018
30268698Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.J Thorac Oncol2018
29599410Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.Clin Cancer Res2018
29125731Imaging PD-L1 Expression with ImmunoPET.Bioconjug Chem2018
27869830Inactivation of Capicua drives cancer metastasis.Nat Genet2017
28287179Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.Sci Rep2017
29106415Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Nat Genet2017
27378174Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.Clin Lung Cancer2016
25843712NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.Cell Rep2015
26301689RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.Nat Med2015
23071030Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.Cancer Discov2012
21999134Emerging antiangiogenic therapies for non-small-cell lung cancer.Expert Rev Anticancer Ther2011
16778221Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy.Cancer Res2006
15689376Developmental stage determines the effects of MYC in the mammary epithelium.Development2005
12138106The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation.J Biol Chem2002
12269832P52rIPK regulates the molecular cochaperone P58IPK to mediate control of the RNA-dependent protein kinase in response to cytoplasmic stress.Biochemistry2002
10799709Tissue specific expression of PKR protein kinase in aging B6D2F1 mice.Mech Ageing Dev2000
11118372Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A.Virology2000
9710605Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation.Mol Cell Biol1998
9447982Regulation of interferon-induced protein kinase PKR: modulation of P58IPK inhibitory function by a novel protein, P52rIPK.Mol Cell Biol1998
  • 1 - 48 of 48

Recommended Authors

Kimberley Avila
University of Texas Southwestern Medical Center
Career Start Year 2017
Number of shared co-authors 1
Arjan Gower
David Geffen School of Medicine at University of California at Los Angeles
Career Start Year 2014
Number of shared co-authors 2
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 2
Margaret Soucheray
J. David Gladstone Institutes
Career Start Year 2012
Number of shared co-authors 4
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 1
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 3
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Vibha Raghavan
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2009
Number of shared co-authors 0
John T Poirier
Laura and Isaac Perlmutter Cancer Center
Career Start Year 2007
Number of shared co-authors 5
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2006
Number of shared co-authors 5
Martin L Sos
University of Cologne, Faculty of Medicine and University Hospital Cologne
Career Start Year 2005
Number of shared co-authors 8
Lecia V Sequist
Massachusetts General Hospital Cancer Center, Harvard Medical School
Career Start Year 2003
Number of shared co-authors 12
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 8
Ming Li
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 1
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 2
Daniel Morgensztern
Washington University School of Medicine
Career Start Year 2000
Number of shared co-authors 6
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 8
Fiona Blackhall
The University of Manchester
Career Start Year 2000
Number of shared co-authors 4
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 11
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 6
Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Career Start Year 1994
Number of shared co-authors 6
Gregory J Riely
Memorial Sloan Kettering Cancer Center
Career Start Year 1994
Number of shared co-authors 14
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 3
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 3
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 25
Pasi A J??nne
Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 16
Roy S Herbst
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 15
Ramaswamy Govindan
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 1981
Number of shared co-authors 11
Hira Rizvi
Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Career Start Year 1978
Number of shared co-authors 11
Ming-Sound Tsao
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 7

Collaborators

Trever G Bivona
University of California san francisco
Co-authored papers 19
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Co-authored papers 12
Victor Olivas
University of California san francisco
Co-authored papers 10
Matthew A Gubens
University of California san francisco
Co-authored papers 10
David M Jablons
University of California, USA Cardiovascular Research Institute san francisco
Co-authored papers 6
Michael G Katze
University of Washington
Co-authored papers 5
Michael Gale
Center for Innate Immunity and Immune Disease, University of Washington
Co-authored papers 4
Saurabh Asthana
University of California San Francisco
Co-authored papers 4
Evangelos Pazarentzos
University of California san francisco
Co-authored papers 3
Victoria Wang
Co-authored papers 3
Luping Lin
Incyte Research Institute, Incyte Corporation
Co-authored papers 3
Dana S Neel
Stanford University School of Medicine
Co-authored papers 3
Gorjan Hrustanovic
University of California san francisco
Co-authored papers 3
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 3
Subba R Digumarthy
Massachusetts General Hospital, USA Harvard Medical School
Co-authored papers 2
Charles Swanton
Francis Crick Institute
Co-authored papers 2
Elton Chan
University of California san francisco
Co-authored papers 2
Jianxing He
Guangzhou Medical University, First Hospital
Co-authored papers 2
Saiama N Waqar
Siteman Cancer Center, Washington University School of Medicine
Co-authored papers 2
Elizabeth Fox
Co-authored papers 1
Jason W Chan
University of California San Francisco
Co-authored papers 1
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 1
Pier Selenica
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Jeffrey R Johnson
Gladstone Institutes
Co-authored papers 1
William L Brown
University of Minnesota
Co-authored papers 1
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
James K Hicks
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 1
Christopher F Bassil
Duke University School of Medicine Durham
Co-authored papers 1
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 1
Dirk De Ruysscher
Maastro Clinic
Co-authored papers 1
Release 1.2